Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

NCT00083525 is registered in ClinicalTrials.gov with Heidelberg Pharma AG as lead sponsor.

NCT NCT00083525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00083525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Lead sponsor
Heidelberg Pharma AG
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2004
Completion date
Not reported
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignancies